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Brucellosis is a chronic multi-systemic epizoonotic infec-
tion that may involve a variety of tissues and organs.
Genitourinary complications are not infrequent (2—10%
of patients with brucellosis may be affected) and include
epididymo-orchitis, pyelonephritis, glomerulonephritis,
interstitial nephritis, oophoritis, and abortion. The inci-
dence of epididymo-orchitis in brucellosis ranges from 1.6%
to 12.7% according to the recent medical literature.1—4
Brucella epididymo-orchitis generally occurs in the sub-
acute phase of the infection and usually requires prolonged
therapy lasting for at least six weeks.1,2,4 Despite the
tendency of Brucella species to cause illness with frequent
relapses, more than two episodes of relapse is rare. We
report herein the triple relapse of epididymo-orchitis in the
same testis in a sexually active young man, despite favor-
able treatment.
A 33-year-old man was admitted to the hospital with a
four-week history of high fever, chills, and profuse night
sweats. His history was otherwise unremarkable and physical
examination showed a fever of 37.5 8C and pulse rate of
80/min; he appeared sick and in pain. Initial blood tests
showed a white blood cell count (WBC) of 3.9  109/l with a
differential of 49% lymphocytes, 43% neutrophils, and 8%
monocytes. The erythrocyte sedimentation rate (ESR) was
24 mm/h, CRP 42 mg/l (normal:<5 mg/l), AST 58 U/l (within
the normal range), and ALT 74 U/l (levels twice the normal).
The standard Brucella tube agglutination test (STA) was
positive at a titer of 1:640. Specific antibiotic therapy for
brucellosis was started with rifampin (600 mg/day) plus dox-
ycycline (200 mg/day), for six weeks. Brucella spp was also
recovered from his blood cultures; the antibiotic suscept-
ibility test was not performed.
Within one week of treatment, enlargement and tender-
ness had developed on the left scrotum. Ultrasonography of
the scrotum revealed unilateral left epididymo-orchitis and
a moderate hypoechoic area was detected. This was con-
sidered as focal orchitis. Testicular elevation was applied
according to the urological recommendation. At the end of
antimicrobial therapy, his fever and scrotal swelling
resolved and STA decreased to 1:160. One month later he
was readmitted to the hospital with fever and left testis
tenderness. STA was positive at a titer of 1:320 and left1201-9712/$32.00 # 2007 International Society for Infectious Diseases.epididymo-orchitis was again detected in the scrotal ultra-
sonography. Considering this a relapse of brucellosis, we
started him on a further six-week treatment with rifampin
plus doxycycline. At the end of the treatment the Brucella
STA had decreased to 1:160, and ESR and CRP had returned
to normal levels. Unfortunately, one month later the
patient was readmitted to our hospital with the same
complaints as before (high fever, left scrotal pain and
tenderness). Scrotal ultrasonography revealed the same
findings and the Brucella STA had increased to a titer of
1:640. Repeated blood cultures were negative. A search for
focal involvement was started for any abscess formation in
other parts of the body, and magnetic resonance imaging
(MRI) showed thoracic spondylitis in the T10—11 space. We
added trimethoprim—sulfamethoxazole to doxycycline plus
ciprofloxacin for Brucella spondylitis and epididymo-orchi-
tis, and the duration of therapy was extended to three
months. As a result of the treatment, the Brucella STA
returned to 1:80 after two months and to 1:40 at the
end of the fourth month, and the patient’s signs and
symptoms were all resolved. On the final follow-up visit
after six months he was all well.
Epididymo-orchitis is the most common and abrupt geni-
tourinary complication of brucellosis. In reported cases, the
relapse rates of epididymo-orchitis in areas where the dis-
ease is endemic show regional differences. For instance,
while Akinci et al.4 and Memish and Venkatesh1 reported a
very low relapse rate from Central Anatolia, Turkey, Navarro-
Martinez et al.5 reported a significantly high rate (25%) from
Spain. In these serial reports, the exact duration of treat-
ment and effective combinations of antimicrobials were not
clearly stated.
In this case, the patient who had received rifampin plus
doxycycline treatment previously at two different times was
admitted for a third time with recurrence of the same side
epididymo-orchitis due to brucellosis. We did not think this a
compliance problem (though it is possible), because his
adherence to treatment was good at the hospital, and after
discharge the records on his drug card supported compliance.
Although there are some studies showing a high relapse rate
with this combination and failure of treatment of genitour-
inary brucellosis, in other studies no significant differences
were found between different treatment combinations.6—8
As clearly seen in our patient (Figure 1), the CRP levels
surging up and down and serological fluctuations are indica-
tive of the relapses.Published by Elsevier Ltd. All rights reserved.
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Figure 1 Relapses of brucellosis and the levels of serum CRP and STA titers in the case.The failure of cure of epididymo-orchitis with doxycycline
plus rifampin combination was interesting. The triple relapse
in our case may indicate that this combination is not an
adequate choice for therapy when this tissue is involved or
that there may be a resistance to one or both of the drugs. On
the other hand, a period of six weeks may not be sufficient for
treatment. For similar patients referred to our institution, it
is essential to obtain an adequate level of combined anti-
biotics in the testicular tissue to resolve the inflammation
rapidly and save the organ from necrotizing orchitis that
usually requires orchiectomy. In conclusion, multiple
relapses in patients with Brucella epididymo-orchitis should
suggest other organ involvement such as osteoarticular tissue
sources or associated brucellar bacteremia or necrotizing
orchitis; such phenomena must carefully be considered.
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thinking
Khan et al. have very meticulously demonstrated an almost
synonymous seropositivity of human papilloma virus 16
(HPV16) among cervical cancer patients in Pakistan.1 The
results call for immediate measures to be taken by the health
authorities in the country, and the suggested connotation
regarding a regular HPV screening of Pakistani women is
verily justified. However, I believe that the implications of
this finding should not be limited to a regular general popula-
tion HPV screening only.
Cervical cancer remains one of the most common malig-
nancies among women around the globe and is the second
leading cause of cancer-related death among women.2
Strong religious and cultural constraints have so far pre-
vented a cervical cancer epidemic in Pakistan, with the
incidence in the female population much lower than breast
and ovarian cancers.3,4 However, with the loosening of cul-
tural boundaries, this may not hold true in a couple of
decades time. Lately, it has been suggested that HPV may
have a causal association with anal, vulvar, and oropharyn-
geal cancers as well.5
Khan and co-workers’ elucidated finding that HPV serotype
16 is responsible for almost all cases of cervical cancer in
Pakistan, implies a lot more than just general population HPV
screening. Two commercial vaccines that cover HPV16 manu-
factured by Merck and GlaxoSmithKline have undergone suc-
cessful advanced clinical trials in the USA.2,6 Moreover, it has
been shown that vaccination against certain viral proteins of
HPV16 induces ananti-viral response thatneutralizes across all
known strains of HPV.7 Owing to the success of the vaccines,
the American Cancer Society now recommends a routine HPV
vaccination for females aged 11—12 years.8 An overwhelming
seropositivity of HPV16 among cervical cancer patients in
Pakistan indicates that preventing the infection of HPV16 by
applying the vaccination strategy could substantially reduce
the incidence of the malignancy in this country.
It is true that the cost—utility of the suggested wide-
population HPV vaccination is yet to be gauged. It does,
however, stand out as a strategy that health authorities in
Pakistan and other developing countries should seriously
consider in the near future, if not now.Conflict of interest: No conflict of interest to declare.
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